* patients with MDS, CMML or AML who were relapsed or
refractory to prior HMA therapies and who received CC-486 had a
38% overall response rate
The post BRIEF-Celgene says patients who recieved prior HMA therapies and CC-486 had a 38 pct overall response rate appeared first on NASDAQ.